- Thursday, January 16, 2025 @ 12:00 am
TransHeps offers objective, patient-specific iDILI (idiosyncratic drug-induced liver injury) causality assessments using patient blood samples. It can be easily integrated into clinical trial workflows. Their biomarker-driven technology helps pharmaceutical and biotech companies reduce clinical trial risks, avoid delays, and ensure safer drug development.
Drug-induced liver injury (DILI) is a leading cause of drug failures, market withdrawals, and clinical trial challenges. The complexity of idiosyncratic DILI, the most unpredictable form of liver injury, demands innovative and precise solutions. TransHeps delivers objective, patient-specific causality assessments by analyzing blood samples from patients.
For companies conducting clinical trials, this approach provides several key advantages. It delivers objective and personalized insights by focusing on patient-specific factors, enabling the identification of liver safety risks with high precision. The method operates with minimal sample requirements, relying solely on patient blood samples, which simplifies integration into clinical trial workflows. By facilitating the early identification of liver injury risks, it reduces costs and delays, helping to prevent expensive late-stage failures and trial interruptions. In contrast to traditional animal models, the approach uses human-relevant solutions that offer greater predictability for human outcomes, improving the reliability of clinical trial results.
